1.800.KIDS DOC | 1.800.543.7362

{{ item.title }}

Susanna McColley, MD

Susanna McColley, MD

Associate Director, Cystic Fibrosis Center Division and Interim Director of Pulmonary Medicine Ann & Robert H. Lurie Children’s Hospital of Chicago

Associate Clinical Director for Child Health, Translational Sciences Institute Professor of Pediatrics, Northwestern University Feinberg School of Medicine

Director, Clinical and Translational Research Program; Deputy Director for Clinical Research, Stanley Manne Children’s Research Institute

Appointments & Referrals

1.800.543.7362 (1.800.KIDS DOC)

About Me

Clinical Interests: Cystic fibrosis, chronic cough, asthma, tobacco prevention and cessation

Specialties, Programs & Conditions

Specialties:

Pediatric Pulmonary Care >

Programs & Conditions:

Cystic Fibrosis Care in Children >

Education & Training

Education: Northwestern University, 1985

Postgraduate Training: Fellowship in pulmonology, Johns Hopkins Hospital, 1988-1991; Residency in pediatrics, Johns Hopkins Hospital, 1985-1988

Board Certifications: Pediatric Pulmonology

Professional Organizations: American Academy of Pediatrics; American College of Chest Physicians; American Thoracic Society

Research

Research Interests: Cystic fibrosis; pediatrics; pulmonary disorders

Publications

Most recent publications

Are children with chronic illnesses requiring dietary therapy at risk for disordered eating or eating disorders? A systematic review Int J Eat Disord 51 (3): 187-213
The relationship between sweat chloride levels and mortality in cystic fibrosis varies by individual genotype J Cyst Fibros 17 (1): 34-42
The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis Expert Opin Drug Saf 16 (11): 1305-1311
Cystic fibrosis year in review 2016 Pediatr Pulmonol 52 (8): 1092-1102
Risk factors for mortality before age 18 years in cystic fibrosis Pediatr Pulmonol 52 (7): 909-915
Diagnosis of Cystic Fibrosis in Screened Populations J Pediatr 181S S33-S44 e2
Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation J Pediatr 181S S4-S15 e1
Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR Ann Am Thorac Soc 14 (2): 213-219
Aminoglycoside resistance of Pseudomonas aeruginosa in cystic fibrosis results from convergent evolution in the mexZ gene Thorax 72 (1): 40-47
Pediatric Pulmonology year in review 2015: Part 4 Pediatr Pulmonol 51 (7): 754-65

Call 1.800.543.7362 for Insurance information. 1.800.543.7362

News

2 Results

Cystic Fibrosis Drug Shows Promise in Children as Young as 1 Year of Age

Study Describes the Good and Bad Lung Bacteria in Cystic Fibrosis Patients

See all News & Stories >